It had posted standalone profit of Rs 25.71 crore for the October-December quarter of 2012-13, Wyeth said in a filing to the BSE.
Total income of the company in Q3, 2013-14 decreased to Rs 161.32 crore, from Rs 170.94 crore in the year-ago period.
More From This Section
Meanwhile, Wyeth said that it has approved the scheme of amalgamation of the company with Pfizer on November 23 with a share swap ratio of seven equity shares valuing Rs 10 of Pfizer with every 10 equity shares of similar value of Wyeth.
"The company is in the process of filing the scheme with the High Court of Bombay... Pending all statutory approvals, no effect of the above scheme has been given in results," Wyeth said.
Wyeth Ltd scrip closed at Rs 709, down 2.99%, on the BSE.